Contents

Search

depemokimab

Indications: - eosinophilic asthma Dosage: - 100 mg subcutaneously twice yearly Mechanism of action: - binds to & inhibits interleukin-5

Interactions

drug adverse effects of pharmaceutical monoclonal antibodies

General

pharmaceutical monoclonal antibody

References

  1. Jackson DJ et al Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med 2024. Sept 9 PMID: 39248309 https://www.nejm.org/doi/full/10.1056/NEJMoa2406673